Clinical trials have consistently demonstrated the superior sensitivity of human papillomavirus (HPV) testing compared with cytology (Pap) testing for identifying women at risk of cervical cancer. Rijkaart et al. have now shown that adding HPV testing to routine cervical cancer screening can further reduce the risk of cervical cancer compared to Pap testing alone.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rijkaart, D. C. et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13, 78–88 (2012).
Ronco, G. et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11, 249–257 (2010).
Naucler, P. et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357, 1589–1597 (2007).
Mayrand, M. H. et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357, 1579–1588 (2007).
Castle, P. E. et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 12, 880–890 (2011).
Sankaranarayanan, R. et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360, 1385–1394 (2009).
Dillner, J. et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337, a1754 (2008).
Katki, H. A. et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 12, 663–672 (2011).
Kitchener, H. C. et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10, 672–682 (2009).
US Preventive Services Task Force. Screening for Cervical Cancer [online] (2012).
Acknowledgements
The views expressed represent only those of the author and do represent the views of The American Society for Clinical Pathology.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
P. E. Castle declares that he serves as a member of a Data and Safety Monitor Board for HPV vaccines on behalf of Merck Sharp & Dohme. P. E. Castle has a non-disclosure agreement with Roche (Pleasanton, CA, USA) to analyze the results of a large clinical trial on HPV testing
Rights and permissions
About this article
Cite this article
Castle, P. More evidence supporting human papillomavirus testing. Nat Rev Clin Oncol 9, 131–132 (2012). https://doi.org/10.1038/nrclinonc.2012.16
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.16
